- Home
- ATNI vs ENGN Comparison
ATNI vs ENGN Comparison
Compare ATNI & ENGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATNI
- ENGN
- Stock Information
- Founded
- ATNI 1987
- ENGN 1999
- Country
- ATNI United States
- ENGN Canada
- Employees
- ATNI N/A
- ENGN N/A
- Industry
- ATNI Telecommunications Equipment
- ENGN
- Sector
- ATNI Telecommunications
- ENGN
- Exchange
- ATNI Nasdaq
- ENGN Nasdaq
- Market Cap
- ATNI 335.2M
- ENGN 297.7M
- IPO Year
- ATNI 1991
- ENGN N/A
- Fundamental
- Price
- ATNI $22.68
- ENGN $5.15
- Analyst Decision
- ATNI Strong Buy
- ENGN Buy
- Analyst Count
- ATNI 2
- ENGN 9
- Target Price
- ATNI $31.00
- ENGN $25.22
- AVG Volume (30 Days)
- ATNI 81.1K
- ENGN 44.3K
- Earning Date
- ATNI 03-04-2025
- ENGN 03-10-2025
- Dividend Yield
- ATNI 4.28%
- ENGN N/A
- EPS Growth
- ATNI N/A
- ENGN N/A
- EPS
- ATNI N/A
- ENGN N/A
- Revenue
- ATNI $729,075,000.00
- ENGN N/A
- Revenue This Year
- ATNI $3.02
- ENGN N/A
- Revenue Next Year
- ATNI $0.27
- ENGN N/A
- P/E Ratio
- ATNI N/A
- ENGN N/A
- Revenue Growth
- ATNI N/A
- ENGN N/A
- 52 Week Low
- ATNI $14.74
- ENGN $4.42
- 52 Week High
- ATNI $33.72
- ENGN $18.40
- Technical
- Relative Strength Index (RSI)
- ATNI 73.12
- ENGN 35.95
- Support Level
- ATNI $19.94
- ENGN $4.85
- Resistance Level
- ATNI $23.60
- ENGN $5.60
- Average True Range (ATR)
- ATNI 1.21
- ENGN 0.53
- MACD
- ATNI 0.43
- ENGN -0.00
- Stochastic Oscillator
- ATNI 87.38
- ENGN 25.69
About ATNI ATN International Inc.
ATN International Inc is a telecommunications and utilities company. The company provides digital infrastructure and communications services with a focus on rural and remote markets in the United States, and internationally, including Bermuda and the Caribbean region. Its operating segments comprise US Telecom and International Telecom. The company earns revenue from its telecommunication services.
About ENGN enGene Holdings Inc.
enGene Holdings Inc is a clinical-stage biotechnology company focused on developing gene therapies to improve the lives of patients. The Company is developing non-viral gene therapies based on its novel and proprietary dually derived chitosan, or DDX, gene delivery platform, which allows localized delivery of multiple gene cargos directly to mucosal tissues and other organs.